MX2021005761A - Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados. - Google Patents
Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.Info
- Publication number
- MX2021005761A MX2021005761A MX2021005761A MX2021005761A MX2021005761A MX 2021005761 A MX2021005761 A MX 2021005761A MX 2021005761 A MX2021005761 A MX 2021005761A MX 2021005761 A MX2021005761 A MX 2021005761A MX 2021005761 A MX2021005761 A MX 2021005761A
- Authority
- MX
- Mexico
- Prior art keywords
- humanized anti
- sirpa antibodies
- sirpa
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18206594 | 2018-11-15 | ||
| PCT/EP2019/081523 WO2020099653A1 (en) | 2018-11-15 | 2019-11-15 | HUMANIZED ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005761A true MX2021005761A (es) | 2021-08-11 |
Family
ID=64331834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005761A MX2021005761A (es) | 2018-11-15 | 2019-11-15 | Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12180295B2 (https=) |
| EP (1) | EP3880707A1 (https=) |
| JP (1) | JP7451520B2 (https=) |
| CN (1) | CN113412279B (https=) |
| AU (1) | AU2019378101B2 (https=) |
| BR (1) | BR112021009275A2 (https=) |
| CA (1) | CA3118966A1 (https=) |
| CL (1) | CL2021001260A1 (https=) |
| IL (1) | IL282756A (https=) |
| MX (1) | MX2021005761A (https=) |
| MY (1) | MY204673A (https=) |
| SG (1) | SG11202104431PA (https=) |
| WO (1) | WO2020099653A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| KR102702926B1 (ko) * | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| AU2021378152A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| TW202317620A (zh) | 2021-06-04 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗ＳＩＲＰα抗體 |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO2001040307A1 (de) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| TR201908314T4 (tr) | 2009-02-20 | 2019-06-21 | 2 Bbb Medicines B V | Glutatyon bazlı ilaç dağıtım sistemi. |
| CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
| US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
| BR112013031762A2 (pt) * | 2011-06-16 | 2016-09-13 | Novartis Ag | proteínas solúveis para utilização como terapêuticos |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| WO2014105910A1 (en) | 2012-12-26 | 2014-07-03 | Oncosynergy, Inc. | ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| CN106456749B (zh) * | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| PL3180363T3 (pl) * | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| BR112018070823A2 (pt) * | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017371070B2 (en) * | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| CN118271443A (zh) * | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
-
2019
- 2019-11-15 JP JP2021526658A patent/JP7451520B2/ja active Active
- 2019-11-15 EP EP19808550.8A patent/EP3880707A1/en active Pending
- 2019-11-15 US US17/292,182 patent/US12180295B2/en active Active
- 2019-11-15 CN CN201980088956.2A patent/CN113412279B/zh active Active
- 2019-11-15 MX MX2021005761A patent/MX2021005761A/es unknown
- 2019-11-15 SG SG11202104431PA patent/SG11202104431PA/en unknown
- 2019-11-15 AU AU2019378101A patent/AU2019378101B2/en active Active
- 2019-11-15 WO PCT/EP2019/081523 patent/WO2020099653A1/en not_active Ceased
- 2019-11-15 MY MYPI2021002647A patent/MY204673A/en unknown
- 2019-11-15 BR BR112021009275A patent/BR112021009275A2/pt unknown
- 2019-11-15 CA CA3118966A patent/CA3118966A1/en active Pending
-
2021
- 2021-04-28 IL IL282756A patent/IL282756A/en unknown
- 2021-05-13 CL CL2021001260A patent/CL2021001260A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022509065A (ja) | 2022-01-20 |
| US12180295B2 (en) | 2024-12-31 |
| SG11202104431PA (en) | 2021-05-28 |
| US20210388107A1 (en) | 2021-12-16 |
| EP3880707A1 (en) | 2021-09-22 |
| CN113412279A (zh) | 2021-09-17 |
| BR112021009275A2 (pt) | 2022-01-04 |
| IL282756A (en) | 2021-06-30 |
| CA3118966A1 (en) | 2020-05-22 |
| CL2021001260A1 (es) | 2021-12-24 |
| AU2019378101B2 (en) | 2025-10-16 |
| CN113412279B (zh) | 2024-09-24 |
| JP7451520B2 (ja) | 2024-03-18 |
| MY204673A (en) | 2024-09-09 |
| WO2020099653A1 (en) | 2020-05-22 |
| KR20210093270A (ko) | 2021-07-27 |
| AU2019378101A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY199247A (en) | ANTI-SIRPa ANTIBODIES | |
| MY204673A (en) | Humanized anti-sirp antibodies | |
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| MX365390B (es) | Anticuerpos pd-1. | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| GEP20237538B (en) | Pd-1-binding molecules and methods of use thereof | |
| GEAP202114756A (en) | Combination therapy for the treatment of cancer | |
| EP3964527A3 (en) | Combination therapy for cancer | |
| PH12012502215A1 (en) | Anti-fgfr2 antibodies | |
| MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
| MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2024000614A (es) | Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer. | |
| MX375221B (es) | Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer. | |
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| WO2016059602A3 (en) | Combination therapy with anti-her3 antibodies to treat cancer | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| PH12016501422B1 (en) | Functionalised benzopyran compounds and use thereof | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| AU2016282877A8 (en) | Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias | |
| ZA201708686B (en) | Nanoparticles for use as a therapeutic vaccine |